OMCL Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of 3.06% compared to Omnicell's net margin of 3.36%. Omnicell's return on equity of -1.47% beat Astrana Health's return on equity of 12.67%.

Omnicell has a consensus price target of --, signalling upside risk potential of 25.77%. On the other hand Astrana Health has an analysts' consensus of $64.5000 which suggests that it could grow by 91.4%. Given that Astrana Health has higher upside potential than Omnicell, analysts believe Astrana Health is more attractive than Omnicell.

Omnicell has a beta of 0.774, which suggesting that the stock is 22.577% less volatile than S&P 500. In comparison Astrana Health has a beta of 1.134, suggesting its more volatile than the S&P 500 by 13.363%.

Omnicell has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omnicell pays -- of its earnings as a dividend. Astrana Health pays out 102.24% of its earnings as a dividend.

Omnicell quarterly revenues are $282.4M, which are smaller than Astrana Health quarterly revenues of $478.7M. Omnicell's net income of $8.6M is lower than Astrana Health's net income of $16.1M. Notably, Omnicell's price-to-earnings ratio is -- while Astrana Health's PE ratio is 25.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell is 1.94x versus 0.93x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of 3.06% compared to Omnicell's net margin of 8.15%. Omnicell's return on equity of -1.47% beat Cryo-Cell International's return on equity of --.

Omnicell has a consensus price target of --, signalling upside risk potential of 25.77%. On the other hand Cryo-Cell International has an analysts' consensus of $9.00 which suggests that it could grow by 14.94%. Given that Omnicell has higher upside potential than Cryo-Cell International, analysts believe Omnicell is more attractive than Cryo-Cell International.

Omnicell has a beta of 0.774, which suggesting that the stock is 22.577% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.501, suggesting its less volatile than the S&P 500 by 49.887%.

Omnicell has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 3.19% to investors and pays a quarterly dividend of $0.25 per share. Omnicell pays -- of its earnings as a dividend. Cryo-Cell International pays out -- of its earnings as a dividend.

Omnicell quarterly revenues are $282.4M, which are larger than Cryo-Cell International quarterly revenues of $8M. Omnicell's net income of $8.6M is higher than Cryo-Cell International's net income of $655.8K. Notably, Omnicell's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell is 1.94x versus 2.03x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of 3.06% compared to Omnicell's net margin of -12.84%. Omnicell's return on equity of -1.47% beat P3 Health Partners's return on equity of -26.35%.

Omnicell has a consensus price target of --, signalling upside risk potential of 25.77%. On the other hand P3 Health Partners has an analysts' consensus of -- which suggests that it could grow by 228.95%. Given that P3 Health Partners has higher upside potential than Omnicell, analysts believe P3 Health Partners is more attractive than Omnicell.

Omnicell has a beta of 0.774, which suggesting that the stock is 22.577% less volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Omnicell has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omnicell pays -- of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.

Omnicell quarterly revenues are $282.4M, which are smaller than P3 Health Partners quarterly revenues of $362.1M. Omnicell's net income of $8.6M is higher than P3 Health Partners's net income of -$46.5M. Notably, Omnicell's price-to-earnings ratio is -- while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell is 1.94x versus 0.02x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.

10x Genomics has a net margin of 3.06% compared to Omnicell's net margin of -23.58%. Omnicell's return on equity of -1.47% beat 10x Genomics's return on equity of -24.99%.

Omnicell has a consensus price target of --, signalling upside risk potential of 25.77%. On the other hand 10x Genomics has an analysts' consensus of $20.29 which suggests that it could grow by 44.49%. Given that 10x Genomics has higher upside potential than Omnicell, analysts believe 10x Genomics is more attractive than Omnicell.

Omnicell has a beta of 0.774, which suggesting that the stock is 22.577% less volatile than S&P 500. In comparison 10x Genomics has a beta of 1.839, suggesting its more volatile than the S&P 500 by 83.931%.

Omnicell has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 10x Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omnicell pays -- of its earnings as a dividend. 10x Genomics pays out -- of its earnings as a dividend.

Omnicell quarterly revenues are $282.4M, which are larger than 10x Genomics quarterly revenues of $151.7M. Omnicell's net income of $8.6M is higher than 10x Genomics's net income of -$35.8M. Notably, Omnicell's price-to-earnings ratio is -- while 10x Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell is 1.94x versus 2.67x for 10x Genomics. Usually stocks with elevated PS ratios are considered overvalued.